Zinc finger protein 139 expression in gastric cancer and its clinical significance

Figure 1 Immunohistochemistry for zinc finger protein 139, Bcl-2, Bax and caspase-3 in gastric cancer and tumor-adjacent tissues. A: Positive ZNF139 expression in GC; B: Negative ZNF139 expression in GC; C: Positive ZNF139 expression in tumor-adjacent tissues; D: Negative ZNF139 expression in tumor-adjacent tissues; E: Positive Bcl-2 expression in GC; F: Negative Bcl-2 expression in GC; G: Positive Bcl-2 expression in tumor-adjacent tissues; H: Negative Bcl-2 expression in tumor-adjacent tissues; I: Positive Bax expression in GC; J: Negative Bax expression in GC; K: Positive Bax expression in tumor-adjacent tissues; L: Negative Bax expression in tumor-adjacent tissues; M: Positive caspase-3 expression in GC; N: Negative caspase-3 expression in GC; O: Positive caspase-3 expression in tumor-adjacent tissues; P: Negative caspase-3 expression in tumor-adjacent tissues; (magnification × 400). ZNF139: Zinc finger protein 139; GC: Gastric cancer.

Figure 2 Kaplan-Meier survival curves of 108 patients with gastric cancer in relation to zinc finger protein 139 expression.

Figure 3 Apoptosis of gastric cancer cells. Photomicrograph showing terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling in gastric cancer cells (× 400).